Key clinical point: Pathologic complete response (pCR) rate was higher in patients with high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) who received neoadjuvant nanoparticle albumin-bound (nab)-paclitaxel vs solvent-based (sb)-paclitaxel.
Major finding: The pCR rate was higher in the overall population receiving nab-paclitaxel vs sb-paclitaxel (20.8% vs 12.9%; P = .002), subgroups with recurrence score of >25 vs ≤25 (16.0% vs 8.4%; P = .021), and endocrine therapy non-responders vs responders (15.1% vs 6.0%; P = .027). Distant disease-free survival was longer in patients who achieved pCR (hazard ratio 0.42; P = .024).
Study details: Findings are from the WSG-ADAPT trial including 864 patients with high-risk HR+/HER2− early BC who were randomly assigned to receive neoadjuvant sb-paclitaxel or nab-paclitaxel, both followed by epirubicin+cyclophosphamide.
Disclosures: This study was supported by Exact Science, Celgene, Amgen, and AOK Rheinland/Hamburg. Some authors declared receiving consulting fees, honoraria, payment, research funding, or travel support, or having other ties with several sources.
Source: Gluz O et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: Results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023 (Apr 14). Doi: 10.1016/j.annonc.2023.04.002